Source:http://linkedlifedata.com/resource/pubmed/id/10708937
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2000-4-20
|
| pubmed:abstractText |
The purpose of this study was to assess the prognostic effect of the expression of E-cadherin, beta-catenin and CD44 adhesion molecules in bladder carcinoma. 22 superficial and 18 invasive bladder tumour samples were studied by immunohistochemistry. The median follow-up was 24 months (range: 1-50 months). Loss of E-cadherin and beta-catenin immunoreactivity was found in 14 (35%) and 17 (43%) tumours, respectively, and was significantly associated with invasiveness, high grade and p53 overexpression. There was no correlation between CD44 variant expression and clinicopathological findings. Loss of E-cadherin expression was an independent predictor of poor survival in a multivariate analysis, when assessed with age, grade, stage and p53 status (hazards ratio adjusted (HRa)=4.45 [95% confidence interval (CI), 1.06-18.63]). This effect was particularly augmented in patients with invasive bladder cancer. When expression of E-cadherin and beta-catenin were evaluated simultaneously, loss of immunoreactivity of both proteins was a strong predictor of poor survival (HRa=13.06 [95% CI, 0.95-178.55]). The same pattern was found when progression-free survival in relation to these variables was assessed. In conclusion, assessment of E-cadherin and beta-catenin immunoreactivity may be a useful prognostic marker in bladder cancer complementary to established prognostic factors.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD44,
http://linkedlifedata.com/resource/pubmed/chemical/CTNNB1 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Cadherins,
http://linkedlifedata.com/resource/pubmed/chemical/Cytoskeletal Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Trans-Activators,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Suppressor Protein p53,
http://linkedlifedata.com/resource/pubmed/chemical/beta Catenin
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Feb
|
| pubmed:issn |
0959-8049
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
36
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
357-62
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:10708937-Aged,
pubmed-meshheading:10708937-Aged, 80 and over,
pubmed-meshheading:10708937-Antigens, CD44,
pubmed-meshheading:10708937-Cadherins,
pubmed-meshheading:10708937-Chi-Square Distribution,
pubmed-meshheading:10708937-Cytoskeletal Proteins,
pubmed-meshheading:10708937-Female,
pubmed-meshheading:10708937-Follow-Up Studies,
pubmed-meshheading:10708937-Humans,
pubmed-meshheading:10708937-Immunohistochemistry,
pubmed-meshheading:10708937-Male,
pubmed-meshheading:10708937-Middle Aged,
pubmed-meshheading:10708937-Multivariate Analysis,
pubmed-meshheading:10708937-Neoplasm Staging,
pubmed-meshheading:10708937-Prognosis,
pubmed-meshheading:10708937-Survival Analysis,
pubmed-meshheading:10708937-Trans-Activators,
pubmed-meshheading:10708937-Tumor Markers, Biological,
pubmed-meshheading:10708937-Tumor Suppressor Protein p53,
pubmed-meshheading:10708937-Urinary Bladder Neoplasms,
pubmed-meshheading:10708937-beta Catenin
|
| pubmed:year |
2000
|
| pubmed:articleTitle |
Prognostic value of the expression of E-cadherin and beta-catenin in bladder cancer.
|
| pubmed:affiliation |
Department of Medical Oncology, Institut Català d'Oncologia, Avda Gran Via Km 2.7, E-08907 L'Hosp. de Llobregat, Barcelona, Spain. garciadelmuro@csub.scs.es
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|